US5824645A
(en)
*
|
1991-12-30 |
1998-10-20 |
Neurex Corporation |
Method of treating inflammation
|
US5591821A
(en)
*
|
1993-07-16 |
1997-01-07 |
The University Of Utah |
Omega-conotoxin peptides
|
US5739276A
(en)
*
|
1994-10-07 |
1998-04-14 |
University Of Utah Research Foundation |
Conotoxin peptides
|
US5623051A
(en)
*
|
1994-11-10 |
1997-04-22 |
University Of Washington |
Methods and compositions for screening for presynaptic calcium channel blockers
|
US5670622A
(en)
*
|
1996-02-15 |
1997-09-23 |
University Of Utah Research Foundation |
Conotoxin peptide PIIIA
|
US6054429A
(en)
*
|
1996-03-08 |
2000-04-25 |
Elan Pharmaceuticals, Inc. |
Epidural method of producing analgesia
|
DK0835126T3
(da)
*
|
1995-06-27 |
2003-07-14 |
Elan Pharm Inc |
Sammensætninger og formuleringer til fremstilling af analgesimidler og til hamning af fremadskridende neuropatiske amertelidelser
|
US5795864A
(en)
*
|
1995-06-27 |
1998-08-18 |
Neurex Corporation |
Stable omega conopetide formulations
|
US5931809A
(en)
|
1995-07-14 |
1999-08-03 |
Depotech Corporation |
Epidural administration of therapeutic compounds with sustained rate of release
|
AU6454096A
(en)
*
|
1995-07-26 |
1997-02-26 |
Warner-Lambert Company |
Use of neuronal calcium channel blockers for the manufacture of a medicament for the treatment of psychoses, schizophrenia and cocaine or amphetamine addiction
|
US5965534A
(en)
*
|
1995-11-22 |
1999-10-12 |
Alcon Laboratories, Inc. |
Use of ω-conotoxin analogs for treating retinal and optic nerve head damage
|
US5776896A
(en)
*
|
1996-01-03 |
1998-07-07 |
Zeneca Limited |
Analgesic peptides from venom of grammostola spatulata and use thereof
|
US6060271A
(en)
*
|
1996-02-09 |
2000-05-09 |
Cornell Research Foundation, Inc. |
CDNA fragments corresponding to voltage gated sodium channel genes expressed in peripheral nerve
|
US5672682A
(en)
*
|
1996-03-18 |
1997-09-30 |
University Of Utah Research Foundation |
Conotoxin peptide PVIIA
|
US6489119B1
(en)
*
|
1996-03-29 |
2002-12-03 |
Elan Pharmaceuticals, Inc. |
Analgesic screening method and composition
|
AU7080698A
(en)
|
1997-04-25 |
1998-11-24 |
Ajinomoto Co., Inc. |
Novel dihydropyridine derivative
|
US5844077A
(en)
|
1997-04-28 |
1998-12-01 |
Cytotherapeutics, Inc. |
Use of conantokins for producing analgesia or for neuroprotection
|
AU9021298A
(en)
*
|
1997-08-15 |
1999-03-08 |
Carolyn Ann Fairbanks |
Agmatine as a treatment for neuropathic pain
|
CA2224066A1
(fr)
*
|
1997-10-24 |
1999-04-24 |
Universite D'ottawa/ University Of Ottawa |
Peptides utilises comme analgesiques
|
CA2315910A1
(fr)
|
1997-12-22 |
1999-07-01 |
Ajinomoto Co., Inc. |
Nouveau derive de dihydropyridine
|
EP1071707A4
(fr)
*
|
1998-04-16 |
2004-12-22 |
Univ Queensland |
Nouveaux peptides d'omega conotoxine
|
AUPP627498A0
(en)
*
|
1998-10-02 |
1998-10-22 |
University Of Queensland, The |
Novel peptides - i
|
US6369193B1
(en)
*
|
1998-10-20 |
2002-04-09 |
University Of Utah Research Foundation |
Contulakin-G, analogs thereof and uses therefor
|
US6268473B1
(en)
|
1999-01-22 |
2001-07-31 |
University Of Utah Research Foundation |
α-conotoxin peptides
|
US6855805B2
(en)
|
1999-01-22 |
2005-02-15 |
University Of Utah Research Foundation |
α-conotoxin peptides
|
US7378400B2
(en)
*
|
1999-02-01 |
2008-05-27 |
University Of Virginia Patent Foundation |
Method to reduce an inflammatory response from arthritis
|
EP1191021A4
(fr)
|
1999-06-23 |
2002-08-07 |
Ajinomoto Kk |
Derive de la dihydropyridine
|
EP1191022A4
(fr)
|
1999-06-23 |
2002-09-18 |
Ajinomoto Kk |
Derive de la dihydropyridine
|
EP1193259A4
(fr)
|
1999-06-23 |
2003-01-29 |
Ajinomoto Kk |
Derives dihydropyrimidiniques
|
NZ517250A
(en)
|
1999-08-10 |
2004-12-24 |
Uab Research Foundation |
Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs (NSAID) and naturally occurring conotoxins
|
JP2003533178A
(ja)
*
|
1999-12-30 |
2003-11-11 |
ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション |
O−スーパーファミリー・コノトキシンペプチド
|
CA2416287A1
(fr)
*
|
2000-07-21 |
2002-01-31 |
University Of Utah Research Foundation |
Omega-conopeptides
|
US20030119731A1
(en)
*
|
2000-07-21 |
2003-06-26 |
University Of Utah Research Foundation |
Omega-conopeptides
|
CA2441889A1
(fr)
*
|
2001-03-23 |
2002-10-03 |
Albert Einstein College Of Medicine Of Yeshiva University |
Procedes permettant d'augmenter l'activite analgesique et d'attenuer les effets excitateurs indesirables d'agonistes opioides agissant de facon bimodale par inhibition du ganglioside gm1
|
CN1269482C
(zh)
*
|
2001-05-18 |
2006-08-16 |
威克斯医药有限公司 |
钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
|
JP4514452B2
(ja)
*
|
2001-10-01 |
2010-07-28 |
ユニバーシティ オブ バージニア パテント ファウンデーション |
A2aアゴニスト活性を有する2−プロピルアデノシン・アナログおよびその組成物
|
ATE381336T1
(de)
*
|
2002-04-10 |
2008-01-15 |
Univ Virginia |
Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
|
EP1572725B1
(fr)
*
|
2002-12-02 |
2012-02-29 |
Xenome Ltd |
Peptides de chi-conotoxine presentant l'acide pyroglutamique n-terminale
|
WO2004050688A1
(fr)
*
|
2002-12-02 |
2004-06-17 |
Xenome Ltd |
Nouveaux peptides de $g(x)-conotoxine (-ii)
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
DE602004007105T2
(de)
|
2003-01-28 |
2008-02-28 |
Microbia Inc., Cambridge |
Zusammensetzung zur behandlung von gastrointestinalen störungen
|
US7365050B2
(en)
*
|
2003-08-08 |
2008-04-29 |
The Regents Of The University Of California |
Methods for modulating a drug-related effect or behavior
|
CA2540895C
(fr)
|
2003-10-02 |
2016-08-02 |
Elan Pharmaceuticals, Inc. |
Combinaisons de ziconotide et d'opioides servant a reduire la douleur
|
CN101068825B
(zh)
*
|
2004-08-02 |
2013-05-08 |
弗吉尼亚大学专利基金会 |
具有a2a激动剂活性的具有修饰的5'-核糖基团的2-丙炔基腺苷类似物
|
WO2006028618A1
(fr)
*
|
2004-08-02 |
2006-03-16 |
University Of Virginia Patent Foundation |
Analogues d'adenosine de propynyle 2-polycyclique presentant des groupes 5'-ribose modifies presentant une activite agoniste de a2a
|
US7442687B2
(en)
*
|
2004-08-02 |
2008-10-28 |
The University Of Virginia Patent Foundation |
2-polycyclic propynyl adenosine analogs having A2A agonist activity
|
CA2577408C
(fr)
*
|
2004-09-10 |
2013-07-09 |
Elena Barbanti |
Utilisation de (halobenzyloxy)benzylamino-propanamides pour la fabrication de medicaments actifs comme modulateurs selectifs des canaux sodiques et/ou calciques
|
US8022177B2
(en)
*
|
2005-09-30 |
2011-09-20 |
The Board Of Trustees Of The University Of Illinois |
Peptides and calcium regulation in mammalian cells
|
US8299211B2
(en)
*
|
2005-09-30 |
2012-10-30 |
The Board Of Trustees Of The University Of Illinois |
Peptides and regulation of calcium channels
|
PT1963280E
(pt)
*
|
2005-12-22 |
2016-02-02 |
Newron Pharm Spa |
Derivados de 2-feniletilamino como cálcio e/ou moduladores do canal de sódio
|
US8178509B2
(en)
*
|
2006-02-10 |
2012-05-15 |
University Of Virginia Patent Foundation |
Method to treat sickle cell disease
|
US8188048B2
(en)
|
2006-06-23 |
2012-05-29 |
Xenome Limited |
Combination therapy
|
AU2008261102B2
(en)
|
2007-06-04 |
2013-11-28 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
HUE038113T2
(hu)
|
2007-06-15 |
2018-09-28 |
Newron Pharm Spa |
Helyettesített 2-[2-(fenil)-etilamino]-alkánamid-származékok és alkalmazásuk nátrium- és/vagy kalciumcsatorna-modulátorokként
|
US8058259B2
(en)
|
2007-12-20 |
2011-11-15 |
University Of Virginia Patent Foundation |
Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
|
EP2328910B1
(fr)
|
2008-06-04 |
2014-08-06 |
Synergy Pharmaceuticals Inc. |
Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
|
EP3241839B1
(fr)
|
2008-07-16 |
2019-09-04 |
Bausch Health Ireland Limited |
Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
|
CA2745694C
(fr)
|
2008-12-03 |
2018-03-27 |
Synergy Pharmaceuticals, Inc. |
Formulations d'agonistes de guanylate cyclase c et methode d'utilisation
|
KR20200111230A
(ko)
|
2008-12-31 |
2020-09-28 |
알데릭스, 인코포레이티드 |
체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 nhe-매개된 역수송을 억제하는 화합물 및 방법
|
WO2018129556A1
(fr)
|
2017-01-09 |
2018-07-12 |
Ardelyx, Inc. |
Composés et procédés pour l'inhibition d'un antiport à médiation par échangeur sodium/proton (nhe) dans le traitement de troubles associés à une rétention d'eau ou à une surcharge en sel et de troubles du tractus gastro-intestinal
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
MX357121B
(es)
|
2011-03-01 |
2018-06-27 |
Synergy Pharmaceuticals Inc Star |
Proceso de preparacion de agonistas c de guanilato ciclasa.
|
CN103781759B
(zh)
|
2011-06-27 |
2016-01-13 |
纽朗制药有限公司 |
氟化的芳基烷基氨基甲酰胺衍生物
|
US10376481B2
(en)
|
2012-08-21 |
2019-08-13 |
Ardelyx, Inc. |
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
|
EP2887964B1
(fr)
|
2012-08-21 |
2019-07-03 |
Ardelyx, Inc. |
Composés et procédés d'inhibition d'un antiport à médiation par nhe dans le traitement de troubles associés à une rétention de fluide ou à une surcharge de sel et de troubles du tractus gastro-intestinal
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
WO2014151206A1
(fr)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonistes de la guanylate cyclase et leurs utilisations
|
PL2983667T3
(pl)
|
2013-04-12 |
2019-10-31 |
Ardelyx Inc |
Związki wiążące nhe3 oraz sposoby inhibicji transportu fosforanów
|
BR112015030326A2
(pt)
|
2013-06-05 |
2017-08-29 |
Synergy Pharmaceuticals Inc |
Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
|
US11602513B1
(en)
|
2016-07-22 |
2023-03-14 |
Flamel Ireland Limited |
Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
|
UY37341A
(es)
|
2016-07-22 |
2017-11-30 |
Flamel Ireland Ltd |
Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
|
US11504347B1
(en)
|
2016-07-22 |
2022-11-22 |
Flamel Ireland Limited |
Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
|
US11602512B1
(en)
|
2016-07-22 |
2023-03-14 |
Flamel Ireland Limited |
Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
|
US11986451B1
(en)
|
2016-07-22 |
2024-05-21 |
Flamel Ireland Limited |
Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
|
AU2018205400B2
(en)
|
2017-01-09 |
2022-07-14 |
Ardelyx, Inc. |
Compounds useful for treating gastrointestinal tract disorders
|
JP2020505333A
(ja)
|
2017-01-09 |
2020-02-20 |
アルデリックス, インコーポレイテッド |
Nhe媒介性アンチポートの阻害薬
|
JP2022522270A
(ja)
|
2019-03-01 |
2022-04-15 |
フラメル アイルランド リミテッド |
食事摂取状態における改善された薬物動態を有するガンマ-ヒドロキシ酪酸塩組成物
|
US11779557B1
(en)
|
2022-02-07 |
2023-10-10 |
Flamel Ireland Limited |
Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
|
US11583510B1
(en)
|
2022-02-07 |
2023-02-21 |
Flamel Ireland Limited |
Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
|